News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ranbaxy Laboratories (RANBAXY.BO) Plans to Relaunch Skin Drug in the US


5/21/2012 7:13:59 AM

India's largest drug maker Ranbaxy Laboratories plans to re-launch its former flagship skincare brand Sotret in the US, that has been banned for almost four years, through a marketing partnership with a Canadian firm Cipher Pharmaceuticals Ltd. "Pre-commercial activities are underway with Ranbaxy Pharmaceuticals, the company's US partner, for a possible launch (of CIP isotretinoin, chemical name of Sotret) in Q4, 2012," Cipher Inc said in its quarterly result report earlier this month. The US drug regulator will have a final review of the drug on May 29, it said. Cipher specialises in developing improved formulations of existing drugs and out-licenses them to partners for a fee. CIP isotretinoin is a new formulation and will be manufactured by Cipher, its CEO Larry Andrews told ET.

Read at India Times

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES